Answers are grounded in this paper and cite their sources.
Background Highly effective CFTR modulator therapies, such as elexacaftor–tezacaftor–ivacaftor (ETI), have transformed cystic fibrosis (CF) care. However, expanding regulatory criteria (such as EMA approval for non-class I variants) create a clinical paradox: patients with rare, uncharacterized mutations gain legal access to modulators without functional proof of efficacy. The rare missense mutation H147P was classified as ETI-resistant based on testing on heterologous expression models, leaving affected patients without targeted options. Here, we evaluated whether the next-generation vanzacaftor/tezacaftor (Vnz/Tez) combination can rescue H147P-CFTR function in native human tissue and translate into clinical benefit in vivo. Methods Primary human nasal epithelial (HNE) cells were isolated from three unrelated CF donors carrying the H147P variant in trans with a minimal function or non-rescuable allele (H147P/W1282X, H147P/G542X, and H147P/N1303K). Cells were differentiated under air-liquid interface (ALI) conditions and treated for 24 h with vehicle, Elx/Tez, or Vnz/Tez prior to short-circuit current measurements in Ussing chambers. Real-world clinical follow-up data (spirometry, sweat chloride, quality of life, and safety) were collected from two patients initiated on vanzacaftor-tezacaftor-deutivacaftor (VTD) therapy; the third patient had not yet started VTD at the time of this report. Results Vehicle-treated patient epithelia displayed negligible baseline CFTR activity. Chronic exposure to Elx/Tez failed to rescue CFTR activity, confirming the ETI-resistant phenotype in native human tissue. In contrast, treatment with Vnz/Tez led to a robust and statistically significant rescue of CFTR-mediated chloride secretion across all three patient samples, reaching approximately 20% to 35% of normal wild-type activity. Both patients treated with VTD demonstrated clinical improvement. Patient GE458 (H147P/W1282X), presenting with end-stage lung disease, experienced an increase in ppFEV1 from 19.7 to 23.6, reduced sputum production, improved daily activity tolerance, and a reduction in sweat chloride from 118 to 74.5 mmol/L. Patient GE494 (H147P/G542X) showed complete resolution of cough, an increase in FEV1 from 96.1% to 100.15% predicted, a decrease in sweat chloride from 91 to 72.5 mmol/L, and substantial gains in CFQ-R quality-of-life scores. Conclusions This study demonstrates that the ETI-resistant H147P-CFTR variant is pharmacologically rescuable by next-generation vanzacaftor-based therapy. By bridging ex vivo primary airway theratyping with real-world in vivo validation, we highlight the power of personalized primary cell platforms to guide prescriptive decisions and close the therapeutic gap for patients carrying selected rare orphan mutations.
No takes yet. Share an insight, caveat, or question.
Pesce et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: